The stock of Ventyx Biosciences Inc (VTYX) has seen a -14.02% decrease in the past week, with a -33.09% drop in the past month, and a 74.77% flourish in the past quarter. The volatility ratio for the week is 5.53%, and the volatility levels for the past 30 days are at 6.80% for VTYX. The simple moving average for the past 20 days is -18.00% for VTYX’s stock, with a -73.82% simple moving average for the past 200 days.
Is It Worth Investing in Ventyx Biosciences Inc (NASDAQ: VTYX) Right Now?
The stock has a 36-month beta value of 0.40. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VTYX is 47.78M, and at present, short sellers hold a 17.53% of that float. On May 01, 2024, the average trading volume of VTYX was 3.96M shares.
VTYX) stock’s latest price update
The stock of Ventyx Biosciences Inc (NASDAQ: VTYX) has decreased by -2.48 when compared to last closing price of 3.84. Despite this, the company has experienced a -14.02% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-30 that Ventyx Biosciences (VTYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Analysts’ Opinion of VTYX
Many brokerage firms have already submitted their reports for VTYX stocks, with Wells Fargo repeating the rating for VTYX by listing it as a “Overweight.” The predicted price for VTYX in the upcoming period, according to Wells Fargo is $16 based on the research report published on March 12, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see VTYX reach a price target of $12. The rating they have provided for VTYX stocks is “Outperform” according to the report published on March 12th, 2024.
Wells Fargo gave a rating of “Equal Weight” to VTYX, setting the target price at $8 in the report published on November 07th of the previous year.
VTYX Trading at -38.29% from the 50-Day Moving Average
After a stumble in the market that brought VTYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.78% of loss for the given period.
Volatility was left at 6.80%, however, over the last 30 days, the volatility rate increased by 5.53%, as shares sank -28.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.03% upper at present.
During the last 5 trading sessions, VTYX fell by -14.02%, which changed the moving average for the period of 200-days by -89.56% in comparison to the 20-day moving average, which settled at $4.49. In addition, Ventyx Biosciences Inc saw 51.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTYX starting from Mohan Raju, who sale 4,312 shares at the price of $5.40 back on Apr 02 ’24. After this action, Mohan Raju now owns 1,578,250 shares of Ventyx Biosciences Inc, valued at $23,299 using the latest closing price.
Krueger Christopher W, the CHIEF BUSINESS OFFICER of Ventyx Biosciences Inc, sale 1,651 shares at $5.40 during a trade that took place back on Apr 02 ’24, which means that Krueger Christopher W is holding 284,999 shares at $8,921 based on the most recent closing price.
Stock Fundamentals for VTYX
The total capital return value is set at -0.81. Equity return is now at value -64.56, with -59.23 for asset returns.
Based on Ventyx Biosciences Inc (VTYX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -13.32. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 56.83.
Currently, EBITDA for the company is -204.55 million with net debt to EBITDA at 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.87.
Conclusion
To sum up, Ventyx Biosciences Inc (VTYX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
